Effects of GH and/or sex steroids on circulating IGF-I and IGFBPs in healthy, aged women and men

American Journal of Physiology - Endocrinology and Metabolism

Volumn 290, Issue 5, 2006, Pages

  Münzer, Thomas ^b   Rosen, Clifford J ^b   Harman, S Mitchell ^b   Pabst, Katherine M ^b   St Clair, Carol ^b   Sorkin, John D ^b   Blackman, Marc R ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NONE

Author keywords

Growth hormone; Insulin like growth factor binding protein

Indexed keywords

GLUCOSE; GROWTH HORMONE; INSULIN; OSTEOCALCIN; SEX HORMONE; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C;

AGED; ARTICLE; BODY WEIGHT; BONE METABOLISM; CONTROLLED STUDY; CROSS LINKING; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; URINARY EXCRETION;

AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; BODY WEIGHT; DOUBLE-BLIND METHOD; ESTRADIOL; FEMALE; GONADAL STEROID HORMONES; HUMAN GROWTH HORMONE; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 4; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 5; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; MALE; MEDROXYPROGESTERONE 17-ACETATE; OSTEOCALCIN; TESTOSTERONE;

EID: 33646393016     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00166.2005     Document Type: Article

References (78)

1. Amin S, Riggs BL, Atkinson EJ, Oberg AL, Melton LJ III, and Khosla S. A potentially deleterious role of IGFBP-2 on bone density in aging men and women. J Bone Miner Res 19: 1075-1083, 2004.
2. Anderson SM, Shah N, Evans WS, Patrie JT, Bowers CY, and Veldhuis JD. Short-term estradiol supplementation augments growth hormone (GH) secretory responsiveness to dose-varying GH-releasing peptide infusions in healthy postmenopausal women. J Clin Endocrinol Metab 86: 551-560, 2001.
3. Arvat E, Ceda G, Ramunni J, Lanfranco F, Aimaretti G, Gianotti L, Broglio F, and Ghigo E. The IGF-I response to very low rhGH doses is preserved in human ageing. Clin Endocrinol (Oxf) 49: 757-763, 1998.
4. Bellantoni MF, Harman SM, Cullins VE, Engelhardt SM, and Blackman MR. Transdermal estradiol with oral progestin: biological and clinical effects in younger and older postmenopausal women. J Gerontol 46: M216-M222, 1991.
5. Bellantoni MF, Vittone J, Campfield AT, Bass KM, Harman SM, and Blackman MR. Effects of oral versus transdermal estrogen on the growth hormone/insulin-like growth factor I axis in younger and older postmenopausal women: a clinical research center study. J Clin Endocrinol Metab 81: 2848-2853, 1996.
6. Benbassat CA, Maki KC, and Unterman TG. Circulating levels of insulin-like growth factor (IGF) binding protein-1 and -3 in aging men: relationships to insulin, glucose, IGF, and dehydroepiandrosterone sulfate levels and anthropometric measures. J Clin Endocrinol Metab 82: 1484-1491, 1997.
7. Blackman MR, Christmas C, Münzer T, O'Connor KG, Stevens TE, Bellantoni MF, Pabst K, St Clair C, Carter HB, Metter EJ, and Harman SM. Influence of testosterone on the GH-IGF-I axis in healthy elderly men. In: Serono Symposia USA Sex Steroid Interactions with Growth Hormone, edited by Giustina A and Veldhuis JD. New York: Springer Verlag, 1999, p. 44-53.
8. Blackman MR, Sorkin JD, Munzer T, Bellantoni MF, Busby-Whitehead J, Stevens TE, Jayme J, O'Connor KG, Christmas C, Tobin JD, Stewart KJ, Cottrell E, St Clair C, Pabst KM, and Harman SM. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA 288: 2282-2292, 2002.
9. Blum WF, Horn N, Kratzsch J, Jorgensen JO, Juul A, Teale D, Mohnike K, and Ranke MB. Clinical studies of IGFBP-2 by radioimmunoassay. Growth Regul 3: 100-104, 1993.
10. Borski RJ, Tsai W, DeMott-Friberg R, and Barkan AL. Regulation of somatic growth and the somatotropic axis by gonadal steroids: primary effect on insulin-like growth factor I gene expression and secretion. Endocrinology 137: 3253-3259, 1996.
11. Burman P, Johansson AG, Siegbahn A, Vessby B, and Karlsson FA. Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. J Clin Endocrinol Metab 82: 550-555, 1997.
12. Ceda GP, Ceresini G, Denti L, Cortellini P, Hoffman AR, and Valenti G. Androgens do not regulate the growth hormone response to GHRH in elderly men. Horm Metab Res 21: 695-696, 1989.
13. Clemmons DR, Snyder DK, and Busby WH Jr. Variables controlling the secretion of insulin-like growth factor binding protein-2 in normal human subjects. J Clin Endocrinol Metab 73: 727-733, 1991.
14. Corpas E, Harman SM, and Blackman MR. Human growth hormone and human aging. Endocr Rev 14: 20-39, 1993.
15. Corpas E, Harman SM, and Blackman MR. Serum IGF-binding protein-3 is related to IGF-I, but not to spontaneous GH release, in healthy old men. Horm Metab Res 24: 543-545, 1992.
16. Corpas E, Harman SM, Pineyro MA, Roberson R, and Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab 75: 530-535, 1992.
17. Dawson-Hughes B, Stern D, Goldman J, and Reichlin S. Regulation of growth hormone and somatomedin-C secretion in postmenopausal women: effect of physiological estrogen replacement. J Clin Endocrinol Metab 63: 424-432, 1986.
18. de Boer H, Blok GJ, Popp-Snijders C, Stuurman L, Baxter RC, and van der Veen E. Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers. J Clin Endocrinol Metab 81: 1371-1377, 1996.
19. Donahue LR, Watson G, and Beamer WG. Regulation of metabolic water and protein compartments by insulin-like growth factor-I and testosterone in growth hormone-deficient lit/lit mice. J Endocrinol 139: 431-439, 1993.
20. Fernholm R, Bramnert M, Hagg E, Hilding A, Baylink DJ, Mohan S, and Thoren M. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease. J Clin Endocrinol Metab 85: 4104-4112, 2000.
21. Fisker S, Norrelund H, Juul A, Skakkebaek NE, Christiansen JS, and Jorgensen JO. The growth hormone (GH)-insulin-like growth factor axis during testosterone replacement therapy in GH-treated hypopituitary males. Growth Horm IGF Res 11: 104-109, 2001.
22. Friend KE, Hartman ML, Pezzoli SS, Clasey JL, and Thorner MO. Both oral and transdermal estrogen increase growth hormone release in postmenopausal women-a clinical research center study. J Clin Endocrinol Metab 81: 2250-2256, 1996.
23. Gentili A, Mulligan T, Godschalk M, Clore J, Patrie J, Iranmanesh A, and Veldhuis JD. Unequal impact of short-term testosterone repletion on the somatotropic axis of young and older men. J Clin Endocrinol Metab 87: 825-834, 2002.
24. Gill MS, Toogood AA, Jones J, Clayton PE, and Shalet SM. Serum leptin response to the acute and chronic administration of growth hormone (GH) to elderly subjects with GH deficiency. J Clin Endocrinol Metab 84: 1288-1295, 1999.
25. Gomez JM, Maravall FJ, Gomez N, Navarro MA, Casamitjana R, and Soler J. The IGF-I system component concentrations that decrease with ageing are lower in obesity in relationship to body mass index and body fat. Growth Horm IGF Res 14: 91-96, 2004.
26. Gori F, Hofbauer LC, Conover CA, and Khosla S. Effects of androgens on the insulin-like growth factor system in an androgen-responsive human osteoblastic cell line. Endocrinology 140: 5579-5586, 1999.
27. Hansen TK, Jorgensen JO, and Christiansen JS. Body composition and circulating levels of insulin, insulin-like growth factor-binding protein-1 and growth hormone (GH)-binding protein affect the pharmacokinetics of GH in adults independently of age. J Clin Endocrinol Metab 87: 2185-2193, 2002.
28. Harman SM and Blackman MR. Use of growth hormone for prevention or treatment of effects of aging. J Gerontol A Biol Sci Med Sci 59: 652-658, 2004.
29. Harman SM, Metter EJ, Tobin JD, Pearson J, and Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 86: 724-731, 2001.
30. Heald A, Selby PL, White A, and Gibson JM. Progestins abrogate estrogen-induced changes in the insulin-like growth factor axis. Am J Obstet Gynecol 183: 593-600, 2000.
31. Ho KK, O'Sullivan AJ, Weissberger AJ, and Kelly JJ. Sex steroid regulation of growth hormone secretion and action. Horm Res 45: 67-73, 1996.
32. Holloway L, Butterfield G, Hintz RL, Gesundheit N, and Marcus R. Effects of recombinant human growth hormone on metabolic indices, body composition, and bone turnover in healthy elderly women. J Clin Endocrinol Metab 79: 470-479, 1994.
33. Honda Y, Landale EC, Strong DD, Baylink DJ, and Mohan S. Recombinant synthesis of insulin-like growth factor-binding protein-4 (IGFBP-4): development, validation, and application of a radioimmunoassay for IGFBP-4 in human serum and other biological fluids. J Clin Endocrinol Metab 81: 1389-1396, 1996.
34. Hwa V, Oh Y, and Rosenfeld RG. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 20: 761-787, 1999.
35. Janssen JA, Stolk RP, Pols HA, Grobbee DE, and Lamberts SW. Serum free and total insulin-like growth factor-I, insulin-like growth factor binding protein-1 and insulin-like growth factor binding protein-3 levels in healthy elderly individuals. Relation to self-reported quality of health and disability. Gerontology 44: 277-280, 1998.
36. Janssen YJ, Helmerhorst F, Frolich M, and Roelfsema F. A switch from oral (2 mg/day) to transdermal (50 microg/day) 17beta-estradiol therapy increases serum insulin-like growth factor-I levels in recombinant human growth hormone (GH)-substituted women with GH deficiency. J Clin Endocrinol Metab 85: 464-467, 2000.
37. Johannsson G, Bjarnason R, Bramnert M, Carlsson LM, Degerblad M, Manhem P, Rosen T, Thoren M, and Bengtsson BA. The individual responsiveness to growth hormone (GH) treatment in GH-deficient adults is dependent on the level of GH-binding protein, body mass index, age, and gender. J Clin Endocrinol Metab 81: 1575-1581, 1996.
38. Jones JI and Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16: 3-34, 1995.
39. Jorgensen JO, Blum WF, Moller N, Ranke MB, and Christiansen JS. Short-term changes in serum insulin-like growth factors (IGF) and IGF binding protein 3 after different modes of intravenous growth hormone (GH) exposure in GH-deficient patients. J Clin Endocrinol Metab 72: 582-587, 1991.
40. Juul A, Pedersen SA, Sorensen S, Winkler K, Jorgensen JO, Christiansen JS, and Skakkebaek NE. Growth hormone (GH) treatment increases serum insulin-like growth factor binding protein-3, bone isoenzyme alkaline phosphatase and forearm bone mineral content in young adults with GH deficiency of childhood onset. Eur J Endocrinol 131: 41-49, 1994.
41. Kam GY, Leung KC, Baxter RC, and Ho KK. Estrogens exert route and dose-dependent effects on insulin-like growth factor (IGF)-binding protein-3 and the acid-labile subunit of the IGF ternary complex. J Clin Endocrinol Metab 85: 1918-1922, 2000.
42. Karjalainen A, Paassilta M, Heikkinen J, Backstrom AC, Savolainen M, and Kesaniemi YA. Effects of peroral and transdermal oestrogen replacement therapy on glucose and insulin metabolism. Clin Endocrinol (Oxf) 54: 165-173, 2001.
43. Kassem M, Brixen K, Mosekilde L, Blum WF, and Flyvbjerg A. Effects of growth hormone treatment on serum levels of insulin-like growth factors (IGFs) and IGF binding proteins 1-4 in postmenopausal women. Clin Endocrinol (Oxf) 49: 747-756, 1998.
44. Kassem M, Okazaki R, De Leon D, Harris SA, Robinson JA, Spelsberg TC, Conover CA, and Riggs BL. Potential mechanism of estrogen-mediated decrease in bone formation: estrogen increases production of inhibitory insulin-like growth factor-binding protein-4. Proc Assoc Am Physicians 108: 155-164, 1996.
45. Lamberts SW, van den Beld AW, and van der Lely AJ. The endocrinology of aging. Science 278: 419-424, 1997.
46. Lu X, Shi Z, and Murphy LJ. Growth hormone suppression of insulin-like growth factor binding protein-1 promoter activity. Mol Cell Endocrinol 149: 19-28, 1999.
47. Mandel S, Moreland E, Nichols V, Hanna C, and Lafranchi S. Changes in insulin-like growth factor-I (IGF-I), IGF-binding protein-3, growth hormone (GH)-binding protein, erythrocyte IGF-I receptors, and growth rate during GH treatment. J Clin Endocrinol Metab 80: 190-194, 1995.
48. Maor G, Segev Y, and Phillip M. Testosterone stimulates insulin-like growth factor-I and insulin-like growth factor-I-receptor gene expression in the mandibular condyle-a model of endochondral ossification. Endocrinology 140: 1901-1910, 1999.
49. Matsumoto AM. Andropause: clinical implications of the decline in serum testosterone levels with aging in men. J Gerontol A Biol Sci Med Sci 57: M76-M99, 2002.
50. Miyakoshi N, Richman C, Kasukawa Y, Linkhart TA, Baylink DJ, and Mohan S. Evidence that IGF-binding protein-5 functions as a growth factor. J Clin Invest 107: 73-81, 2001.
51. Miyakoshi N, Richman C, Qin X, Baylink DJ, and Mohan S. Effects of recombinant insulin-like growth factor-binding protein-4 on bone formation parameters in mice. Endocrinology 140: 5719-5728, 1999.
52. Mohan S, Libanati C, Dony C, Lang K, Srinivasan N, and Baylink DJ. Development, validation, and application of a radioimmunoassay for insulin-like growth factor binding protein-5 in human serum and other biological fluids. J Clin Endocrinol Metab 80: 2638-2645, 1995.
53. Mohan S, Nakao Y, Honda Y, Landale E, Leser U, Dony C, Lang K, and Baylink DJ. Studies on the mechanisms by which insulin-like growth factor (IGF) binding protein-4 (IGFBP-4) and IGFBP-5 modulate IGF actions in bone cells. J Biol Chem 270: 20424-20431, 1995.
54. Molnar P and Murphy LJ. Effects of oestrogen on rat uterine expression of insulin-like growth factor-binding proteins. J Mol Endocrinol 13: 59-67, 1994.
55. Nystrom FH, Ohman PK, Ekman BA, Osterlund MK, Karlberg BE, and Arnqvist HJ. Population-based reference values for IGF-I and IGF-binding protein-1: relations with metabolic and anthropometric variables. Eur J Endocrinol 136: 165-172, 1997.
56. Paassilta M, Karjalainen A, Kervinen K, Savolainen MJ, Heikkinen J, Backstrom AC, and Kesaniemi YA. Insulin-like growth factor binding protein-1 (IGFBP-1) and IGF-I during oral and transdermal estrogen replacement therapy: relation to lipoprotein(a) levels. Atherosclerosis 149: 157-162, 2000.
57. Papadakis MA, Grady D, Black D, Tierney MJ, Gooding GA, Schambelan M, and Grunfeld C. Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med 124: 708-716, 1996.
58. Phillip M, Palese T, Hernandez ER, Roberts CT Jr, LeRoith D, and Kowarski AA. Effect of testosterone on insulin-like growth factor-I (IGF-I) and IGF- I receptor gene expression in the hypophysectomized rat. Endocrinology 130: 2865-2870, 1992.
59. Rajaram S, Baylink DJ, and Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 18: 801-831, 1997.
60. Raynaud-Simon A. Levels of plasma insulin-like growth factor I (IGF I), IGF II, IGF binding proteins, type 1 IGF receptor and growth hormone binding protein in community-dwelling elderly subjects with no malnutrition and no inflammation. J Nutr Health Aging 7: 267-273, 2003.
61. Rietveld I, Janssen JA, Hofman A, Pols HA, van Duijn CM, and Lamberts SW. A polymorphism in the IGF-I gene influences the age-related decline in circulating total IGF-I levels. Eur J Endocrinol 148: 171-175, 2003.
62. Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF, Schlenker RA, Cohn L, Rudman IW, and Mattson DE. Effects of human growth hormone in men over 60 years old. N Engl J Med 323: 1-6, 1990.
63. Rutanen EM, Karkkainen T, Stenman UH, and Yki-Jarvinen H. Aging is associated with decreased suppression of insulin-like growth factor binding protein-1 by insulin. J Clin Endocrinol Metab 77: 1152-1155, 1993.
64. Snyder DK and Clemmons DR. Insulin-dependent regulation of insulin-like growth factor-binding protein-1. J Clin Endocrinol Metab 71: 1632-1636, 1990.
65. Suikkari AM, Koivisto VA, Rutanen EM, Yki-Jarvinen H, Karonen SL, and Seppala M. Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein. J Clin Endocrinol Metab 66: 266-272, 1988.
66. Svensson J, Ohlsson C, Jansson JO, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Baylink D, Mohan S, and Bengtsson BA. Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males. J Bone Miner Res 13: 1158-1166, 1998.
67. Taieb J, Mathian B, Millot F, Patricot MC, Mathieu E, Queyrel N, Lacroix I, Somma-Delpero C, and Boudou P. Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. Clin Chem 49: 1381-1395, 2003.
68. Thoren M, Hilding A, Baxter RC, Degerblad M, Wivall-Helleryd IL, and Hall K. Serum insulin-like growth factor I (IGF-I), IGF-binding protein-1 and -3, and the acid-labile subunit as serum markers of body composition during growth hormone (GH) therapy in adults with GH deficiency. J Clin Endocrinol Metab 82: 223-228, 1997.
69. Thoren M, Hilding A, Brismar T, Magnusson P, Degerblad M, Larsson L, Saaf M, Baylink DJ, and Mohan S. Serum levels of insulin-like growth factor binding proteins (IGFBP)-4 and -5 correlate with bone mineral density in growth hormone (GH)- deficient adults and increase with GH replacement therapy. J Bone Miner Res 13: 891-899, 1998.
70. Ueland T, Brixen K, Mosekilde L, Flyvbjerg A, and Bollerslev J. Age-related changes in cortical bone content of insulin-like growth factor binding protein (IGFBP)-3, IGFBP-5, osteoprotegerin, and calcium in postmenopausal osteoporosis: a cross-sectional study. J Clin Endocrinol Metab 88: 1014-1018, 2003.
71. Urban RJ, Bodenburg YH, Gilkison C, Foxworth J, Coggan AR, Wolfe RR, and Ferrando A. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol Endocrinol Metab 269: E820-E826, 1995.
72. van den Beld AW, Blum WF, Pols HA, Grobbee DE, and Lamberts SW. Serum insulin-like growth factor binding protein-2 levels as an indicator of functional ability in elderly men. Eur J Endocrinol 148: 627-634, 2003.
73. Veldhuis JD, Anderson SM, Iranmanesh A, and Bowers CY. Testosterone blunts feedback inhibition of growth hormone secretion by experimentally elevated insulin-like growth factor-I concentrations. J Clin Endocrinol Metab 90: 1613-1617, 2005.
74. Veldhuis JD, Liem AY, South S, Weltman A, Weltman J, Clemmons DA, Abbott R, Mulligan T, Johnson ML, Pincus S, Straume M, and Iranmanesh A. Differential impact of age, sex steroid hormones, and obesity on basal versus pulsatile growth hormone secretion in men as assessed in an ultrasensitive chemiluminescence assay. J Clin Endocrinol Metab 80: 3209-3222, 1995.
75. Washburn RA, Smith KW, Jette AM, and Janney CA. The Physical Activity Scale for the Elderly (PASE): development and evaluation. J Clin Epidemiol 46: 153-162, 1993.
76. Waters DL, Yau CL, Montoya GD, and Baumgartner RN. Serum sex hormones, IGF-1, and IGFBP-3 exert a sexually dimorphic effect on lean body mass in aging. J Gerontol A Biol Sci Med Sci 58: 648-652, 2003.
77. Wolk K, Larsson SC, Vessby B, Wolk A, and Brismar K. Metabolic, anthropometric, and nutritional factors as predictors of circulating insulin-like growth factor binding protein-1 levels in middle-aged and elderly men. J Clin Endocrinol Metab 89: 1879-1884, 2004.
78. Zhang M, Faugere MC, Malluche H, Rosen CJ, Chernausek SD, and Clemens TL. Paracrine overexpression of IGFBP-4 in osteoblasts of transgenic mice decreases bone turnover and causes global growth retardation. J Bone Miner Res 18: 836-843, 2003.